Quarterly report pursuant to Section 13 or 15(d)

Debt - Additional Information (Details)

Debt - Additional Information (Details)				3 Months Ended		12 Months Ended	38 Months Ended
Debt - Additional Information (Details)	Sep. 08, 2020 USD ($) Debtinstrument $ / shares shares	Jan. 21, 2020 USD ($) Debtinstrument $ / shares shares	Apr. 27, 2018 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2024 USD ($) shares
Debt Instrument [Line Items]
Accretion of debt discounts and deferred financing costs				$ 569,000	$ 578,000
Aggregate principal amount of exchangeable notes							$ 40,691,000
Issuance of ordinary shares on conversion of exchangeable notes (in shares) \| shares							3,760,155
Loan and Security Agreement \| Silicon Valley Bank (SVB)
Debt Instrument [Line Items]
Loan and security agreement entered date				Apr. 27, 2018
Funded amount under agreement			$ 15,000,000
Remaining borrowing facility available date			Oct. 31, 2019
Maximum amount available under agreement			$ 30,000,000
Final interest rate payment on outstanding principal			4.20%
Principal and interest payment, maturity date			Mar. 01, 2022
Loan and Security Agreement \| Silicon Valley Bank (SVB) \| Maximum
Debt Instrument [Line Items]
Maximum amount available under second draw			$ 15,000,000
Silicon Valley Bank and Life Sciences Fund II LLC \| Ordinary Shares
Debt Instrument [Line Items]
Number of warrants to purchase ordinary shares \| shares			1,326
Silicon Valley Bank and Life Sciences Fund II LLC \| Series B Convertible Preferred Shares
Debt Instrument [Line Items]
Number of warrants to purchase ordinary shares \| shares			19,890
Warrants to purchase preferred shares, exercise price \| $ / shares			$ 282.75
2025 Exchangeable Notes
Debt Instrument [Line Items]
Interest expense				$ 181,000	205,000
Accretion of debt discounts and deferred financing costs				569,000	$ 578,000
Aggregate principal amount		$ 9,891,000		11,117,000			$ 11,117,000
Debt instrument, outstanding principal				$ 11,117,000			$ 11,117,000
Debt instrument, payment terms				The Company will be required to pay each holder of the Exchangeable Notes the greater of three times the outstanding principal amount of such Exchangeable Note and the consideration that would be received by the holder of such Exchangeable Note in connection with such Fundamental Change if the holder had exchanged its note for ordinary shares immediately prior to the consummation of such Fundamental Change, plus any accrued and unpaid interest.
Fair value of derivative liability		27,038,000
Fair value of derivative liability related to rights offering	$ 82,000
Financing transaction costs						$ 2,848,000
Financing transaction costs, capitalized						$ 2,814,000
2025 Exchangeable Notes \| Private Placement
Debt Instrument [Line Items]
Aggregate principal amount		51,588,000
Debt instrument price per unit	1,000	$ 1,000
2025 Exchangeable Notes \| Private Placement and Rights Offering
Debt Instrument [Line Items]
Aggregate principal amount	51,800,000
Debt instrument interest rate		6.50%
2025 Exchangeable Notes \| Rights Offering
Debt Instrument [Line Items]
Aggregate principal amount	$ 220,000
RLNs \| Private Placement
Debt Instrument [Line Items]
Aggregate principal amount		$ 103,000
Number of debt instruments within each notes \| Debtinstrument	50	50
RLNs \| Private Placement and Rights Offering
Debt Instrument [Line Items]
Aggregate principal amount	$ 500	$ 100,000
RLNs \| Rights Offering
Debt Instrument [Line Items]
Aggregate principal amount	440
Securities \| Private Placement
Debt Instrument [Line Items]
Debt instrument price per unit	$ 1,000	$ 1,000
Debt instrument, shares embedded within each unit, shares \| shares	66.666	66.666		104.4282
Debt instrument, shares embedded within each unit, value	$ 1,000	$ 1,000		$ 1,000
Debt instrument, shares embedded within each unit, exchange price \| $ / shares	$ 15	$ 15		$ 9.576